Browsed by
Month: September 2018

Creatv MicroTech Receives DoD Funding for Lung Cancer Screening

Creatv MicroTech Receives DoD Funding for Lung Cancer Screening

ROCKVILLE, MD, September 14, 2018
Creatv MicroTech, Inc. (Creatv) has received a $625,000 award from the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) to investigate their discovery of giant circulating cells found in peripheral blood for non-invasive detection of lung cancer by differentiating malignant from benign pulmonary nodules detected by low dose CT (LDCT). In the three-year study, Creatv will examine blood samples from 1,250 subjects at high risk for lung cancer based on their smoking history and occupational exposure to carcinogens. ...  Read more

SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.

SERAXIS Inc. announces novel method and cell line that generate highly pure populations of insulin-producing cells capable of reversing diabetes in rodents.

GERMANTOWN, Md.Sept. 5, 2018 /PRNewswire/ — SERAXIS Inc., a privately held regenerative medicine company today announced the successful production of stem cell derived pancreatic cells capable of regulating blood glucose in rodent models of insulin dependent diabetes. ...  Read more

Veralox Success Story

Veralox Success Story

FREDERICK, Md.Aug. 31, 2018 /PRNewswire-PRWeb/ — Rare blood disorders are on VERALOX Therapeutics Inc.’s “hit” list. The company, a small molecule drug discovery and development firm based in the Frederick Innovative Technology Center, Inc. (FITCI), launched in September 2017 with a mission to develop a first-in-class therapeutic targeting rare immune-mediated blood disorders, beginning with heparin-induced thrombocytopenia (HIT) and HIT with thrombosis (HITT). ...  Read more